Veeva Systems today announced that LEO Pharma, an international leader in medical dermatology, has selected Veeva Development Cloud applications to help boost process end-to-end business on all product development. The company will use the Vault Clinical , Vault RIM , and Vault Quality suites to unify drug development on a single platform in the cloud. With Veeva Development Cloud, LEO Pharma can bring applications together in the clinical, regulatory and quality environments for increased efficiency and compliance throughout the product development lifecycle.
"The research and development of LEO Pharma has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to be at the forefront of dermatology. It requires us to be able to advance science around the world, while at the same time securing timely delivery of our industry, "said Kim Kjøller, Executive Vice President of Global Research and Development. at LEO Pharma. "Veeva Development Cloud provides us with a unified platform that can enable us to maximize efficiency throughout product development and evolve as we grow toward our goals. We will now be able to streamline product development around the world and accelerate delivery of new treatments for even more patients. "
LEO Pharma aims to reach 125 million patients with chronic and severe skin conditions by 2025. To expand its drug development efforts, the company has made several significant acquisitions and established platforms in the United States and China. . Veeva Development Cloud provides LEO Pharma global teams with a single source for product development information to better ensure compliance and enhance global collaboration.
"Veeva is helping us transform our entire research and development business," said Mika Välilä, Senior Director of Digital Business Platforms, Global IT, for LEO Pharma. "Veeva Development Cloud enables us to ensure greater consistency and productivity across all product development efforts in clinical trials, regulatory issues and quality. "
LEO Pharma today uses Vault eTMF , Vault Submissions , and Vault QualityDocs . In 2019, the company will add Vault CTMS , Vault Study Startup , Vault Registrations , and Vault QMS to further streamline the product development lifecycle across all regions and departments.
"LEO Pharma is a great example of how organizations are modernizing their core business functions," said Rik Van Mol, vice president of Veeva's European Veeva Development Cloud Strategy. "Veeva Development Cloud provides life sciences companies with the foundation for eliminating system, site, and country compartments across all drug development. "
Listen to LEO Pharma and other customers discuss why they are standardizing on Veeva Development Cloud at the upcoming Veeva European Research and Development Summit , June 11-13, 2019 in Barcelona, ??Spain. Check out the program and sign up at veeva.com/eu/events/rd-summit .
Additional Information
To learn more about Veeva Development Cloud, visit: veeva.com/development-cloud
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About LEO Pharma
LEO Pharma helps patients to have healthy skin. With a solid pipeline of research and development, a wide range of therapies and a forward-thinking spirit, the company is a leader in medical dermatology. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has dedicated decades of research and development to advance the science of dermatology, setting new standards of care for people with skin diseases. LEO Pharma is headquartered in Denmark and has a global team of 5,500 employees serving 76 million patients in 130 countries. In 2018, the company achieved a turnover of 10 410 million DKK. For more information, visit www.linkedin.com/company/leo-pharma or www.leo-pharma.com .
About Veeva Systems
Veeva Systems Inc. is the leading provider of cloud-based software for the global life sciences industry. Betting on innovation, product excellence, and customer success, Veeva serves more than 700 customers from leading global pharmaceutical companies to emerging biotechnology companies. Headquartered in the San Francisco Bay Area, Veeva has offices throughout North America, Europe, Asia and Latin America. For more information, visit veeva.com .
Forward-looking statements
This press release contains forward-looking statements, including market demand and acceptance, Veeva's products and services, the results of the use of Veeva's products and services, and the general terms and conditions of business, in particular in the life sciences industry. All forward-looking statements in this press release are based on Veeva's historical performance and current plans, estimates and expectations, and do not represent a guarantee that such plans, estimates, or expectations will be realized. These forward-looking statements represent Veeva's expectations as of the date of this press release. Subsequent events may vary these expectations, and Veeva disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expected. Other risks and uncertainties that could affect Veeva's financial results are included under the headings "Risk Factors" and "Management Discussion and Analysis of Financial Condition and Results of Operations" in the Company's report. on Form 10-Q for the period ending October 31, 2018. It is available on the Company's website at These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expected. Other risks and uncertainties that could affect Veeva's financial results are included under the headings "Risk Factors" and "Management Discussion and Analysis of Financial Condition and Results of Operations" in the Company's report. on Form 10-Q for the period ending October 31, 2018. It is available on the Company's website at These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from those expected. Other risks and uncertainties that could affect Veeva's financial results are included under the headings "Risk Factors" and "Management Discussion and Analysis of Financial Condition and Results of Operations" in the Company's report. on Form 10-Q for the period ending October 31, 2018. It is available on the Company's website at veeva.com under the Investors section, and on the SEC's website at sec.gov . Further information on potential risks that could affect actual results will be included in other documents filed from time to time by Veeva with the SEC.
The text of the press release resulting from a translation must in no way be considered official. The only version of the release that is authentic is that of the release in its original language. The translation will always have to be confronted with the source text, which will make jurisprudence.
Register as Visitor to CPhI China 2019!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight JANUARY 2024
